文献速递神经肿瘤

贝伐珠单抗-IRDye800CW用于荧光引导脑膜瘤手术中的肿瘤检测(LUMINA试验):一项单中心I期研究

Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study.
PubMed 文献 · J Neurosurg · 2024-07-05

这项前瞻性I期试验旨在确定贝伐珠单抗-IRDye800CW用于颅内脑膜瘤分子荧光引导手术的安全性和可行性,术前2-4天给予4.5、10或25 mg示踪剂。结果显示无相关不良事件,10 mg为基于离体肿瘤-背景比的最优剂量,术后定制成像系统显示肿瘤高荧光摄取,且荧光强度与VEGFα表达良好相关。

要点

  • 贝伐珠单抗-IRDye800CW在脑膜瘤患者中可安全使用,未发生相关不良事件。
  • 基于离体肿瘤-背景比,10 mg为最优剂量。
  • 标准术中显微镜未显示荧光,需调整现有设备以实现术中可视化。

核心结论

  • 贝伐珠单抗-IRDye800CW可安全用于脑膜瘤患者;10 mg贝伐珠单抗-IRDye800CW提供了足够的肿瘤-背景比。
  • 需要调整现有神经外科显微镜以实现术中靶向IRDye800CW的可视化。
  • 需要进行II/III期试验以在更大队列中系统研究贝伐珠单抗-IRDye800CW用于脑膜瘤手术的分子荧光引导手术的获益。

研究设计与样本

  • 前瞻性I期试验,单中心,旨在确定贝伐珠单抗-IRDye800CW用于颅内脑膜瘤分子荧光引导手术的安全性和可行性。
  • 术前2-4天给予4.5、10或25 mg示踪剂。
  • 术中采用标准神经外科显微镜验证荧光,术后采用荧光成像系统(Pearl和Odyssey CLx)和光谱学分析组织标本以确定最优剂量。
  • 比较多种组织类型的摄取并与VEGFα表达进行相关性分析。

主要发现

  • 未发生与贝伐珠单抗-IRDye800CW使用相关的不良事件。
  • 经过两次中期分析,基于离体肿瘤-背景比确定10 mg为最优剂量。
  • 标准术中成像未显示荧光,但术后采用定制成像系统分析显示肿瘤较未受累硬脑膜和脑组织有高荧光摄取。
  • 荧光成像可区分硬脑膜肿瘤侵犯(硬脑膜尾征)和骨侵犯。
  • 荧光强度与VEGFα表达显示良好相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas are one of the most frequently occurring brain tumors and can be curatively treated with gross-total resection. A subtotal resection increases the chances of recurrence. The intraoperative identification of invisible tumor remnants by using a fluorescent tracer targeting an upregulated biomarker could help to optimize meningioma resection. This is called molecular fluorescence-guided surgery (MFGS). Vascular endothelial growth factor α (VEGFα) has been identified as a suitable meningioma biomarker and can be targeted with bevacizumab-IRDye800CW. METHODS: The aim of this prospective phase I trial was to determine the safety and feasibility of bevacizumab-IRDye800CW for MFGS for intracranial meningiomas by administering 4.5, 10, or 25 mg of the tracer 2-4 days prior to surgery. Fluorescence was verified during the operation with the standard neurosurgical microscope, and tissue specimens were postoperatively analyzed with fluorescence imaging systems (Pearl and Odyssey CLx) and spectroscopy to determine the optimal dose. Uptake was compared in several tissue types and correlated with VEGFα expression. RESULTS: No adverse events related to the use of bevacizumab-IRDye800CW occurred. After two interim analyses, 10 mg was the optimal dose based on ex vivo tumor-to-background ratio. Although the standard intraoperative imaging revealed no fluorescence, postoperative analyses with tailored imaging systems showed high fluorescence uptake in tumor compared with unaffected dura mater and brain. Additionally, tumor invasion of the dura mater (dural tail) and invasion of bone could be distinguished using fluorescence imaging. Fluorescence intensity showed a good correlation with VEGFα expression. CONCLUSIONS: Bevacizumab-IRDye800CW can be safely used in patients with meningioma; 10 mg bevacizumab-IRDye800CW provided an adequate tumor-to-background ratio. Adjustments of the currently available neurosurgical microscopes are needed to achieve visualization of targeted IRDye800CW intraoperatively. A phase II/III trial is needed to methodically investigate the benefit of MFGS with bevacizumab-IRDye800CW for meningioma surgery in a larger cohort of patients.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Dijkstra BM, Cordia QCF, Nonnekens J, et al. Bevacizumab-IRDye800CW for tumor detection in fluorescence-guided meningioma surgery (LUMINA trial): a single-center phase I study. J Neurosurg. 2024. PMID: 38968617. doi:10.3171/2024.4.JNS232766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。